Life Sciences & Health Care M&A Advisory

We are the leading mid-market M&A advisor to the Life Sciences & Healthcare sector. We are passionate about working with companies that make a positive impact on the lives of patients.
Life Sciences & Health Care M&A Advisory

Our services

We provide M&A advisory services to owner-managers, private equity and corporate clients on sell-side and buy-side transactions. In close dialogue with our clients, we advise on the strategic, financial and commercial aspects of the transaction process and project manage transactions through to completion.

Our dedicated life sciences and healthcare M&A team is integrated with Deloitte’s Global Life Sciences & Healthcare practice, including the UK Deloitte Centre for Healthcare Solutions, bringing the very best in market knowledge and thought leadership to the clients that we advise.

We provide a full range of financial advisory services across sub-industries, including healthcare services, pharmaceutical services, consumer healthcare, medical devices, health tech and healthcare IT.

Merger market logo

Mergermarket

#1 Global & European M&A Advisor across all sectors and in the Life Sciences & Healthcare sector in 2022 (by deal volume)
HealthInvestor Awards

HealthInvestor Awards

‘Corporate Financier of the Year’ for 6 out of the last 8 years
LaingBuisson Awards

LaingBuisson Awards

‘Financial Advisor of the Year’ for 4 out of the last 8 years

Our purpose in action

At Deloitte, we believe in making a positive impact on the lives of patients by helping to build healthcare companies of the future. Watch our videos to learn more.

Safe Obstetrics Systems


We are proud to have worked with Safe Obstetric Systems on their deal with Cooper Surgical. This deal has helped enhance the international accessibility of the Fetal Pillow – a medical device proven to help safely deliver babies in emergency c-sections and save hospital resources. Over 60,000 babies have been safely delivered using the emergency caesarean section medical device.

OKRA Technologies


We are proud to have worked with OKRA on its sale to Envision Pharma Group. OKRA is a pioneer in developing AI solutions for the life science industry, bringing self-learning AI to optimise commercial, medical and market access decision making. OKRA solutions have commercially supported drugs addressing over 65 indications.

Our work

nov 2023
oct 2023

What our clients say

We wanted to express our appreciation for the enormous contribution that the Deloitte Team made in bringing the Ashdale deal to such a successful completion. Everyone on the Deloitte Team made a really positive impact on all fronts. The success of this deal is hugely significant to MML Ireland. We would not have had this success without Deloitte as a partner and we are massively appreciative of that.
Rory Quirke Director & Co-Head Investments, MML



Our collaboration with the unparalleled Deloitte Life Sciences Advisory Corporate team, expertly guided by the insightful Amar Shah, has exceeded all expectations and taken our success to new heights. Their unwavering commitment to providing exceptional support and guidance throughout the transaction process was instrumental in helping us secure the ideal partner with the optimal synergies to integrate OKRA.ai’s cutting-edge AI technology with Envision’s consulting capability and unique data assets, offering our customers maximum value. The Deloitte team’s deep industry knowledge and astute understanding of the buyer landscape was invaluable, proving to be the catalyst for our remarkable success. As a compact but mighty management team, we are sincerely grateful for the level of expertise and support provided by the Deloitte team, who played a crucial role in securing our success.
Loubna Bouarfa CEO & Founder, OKRA Technologies



Following a rigorous selection process, we appointed Deloitte to explore sale options for BioPhorum in early 2021. Following a number of pre-emptive bids, we concluded an accelerated sale in May 2021 which provided an exceptional outcome for all shareholders. David and Amar were both important and instrumental to Deloitte obtaining the mandate and, furthermore, provided invaluable strategic and tactical advice in a fluid and sensitive set of negotiations with BioPhorum shareholders and buyers.
Tom Chaloner Partner, Vespa Capital & Board member, BioPhorum Group



Their relationship management and support was second to none from big picture strategy down to the technical details. The commitment and focus they showed was unwavering. The team were very professional and they truly cared about getting the best outcome for us.
Cameron Crockett Managing Partner, Kester Capital & Board member, Frontier Medical Group



I want to thank the Deloitte team for the hugely valuable support that you have given us. We would not have been able to get here without your advice and considerable expertise. I am particularly impressed with the fact that whilst we must be your smallest client (with potentially one of your more demanding deal processes), we have always felt that we were your only client/priority.
Michael Steel CEO, Greenbrook Healthcare






I can highly recommend working with Deloitte – deep sector expertise, hands on approach and attention to detail, great communication and easy to work with. Deloitte demonstrated an absolute commitment to maximise value and a pragmatic approach to the inevitable hurdles you encounter on every deal.
Richard McKenzie CEO, Christchurch Group



Deloitte demonstrated added value and managed the overall process very well, including doing significant heavy lifting. Their ability to manage complex negotiations was impressive. I’d have no hesitation in working with you again. I’d highly recommend!
Neil Cooper Chairman & Founder, Preventx



The Deloitte team did an excellent job and provided expert advice throughout the transaction and, most importantly, their hands on approach ensured the deal crossed the line.
Stephen Blatchford Executive Chairman, Blatchford



What makes Deloitte distinctive? Plenty of communication, reputation in the healthcare market, know when to negotiate and when to give in. The team acted with integrity, skill and were easy to get on with.
Tim Lee CEO, Helping Hands



I would like to thank the Deloitte team for the excellent support and advice they provided during this transaction. We were thoroughly impressed with their hands on approach and extensive knowledge of our sector which added real value and ensured a very smooth process.
James Gunton Partner, Exponent & Board member, BBI Group



We carried out a thorough selection process… I wanted an advisor who not only truly understood my business but who also had strong relationships with the international buyers. We have a small management team and we needed an advisor who could be patient with us but also never miss a beat on data requests. I am extremely happy that I had David and Amar negotiating for me - I couldn’t recommend the Deloitte team more highly.
Jilani Gulam CEO, Health iQ

Our global practice

As the world’s largest professional services firm, we have an unparalleled global network of advisors operating across the full corporate finance and consulting spectrum.

Our global reach and strong relationships with corporate and private equity acquirers provide us with unrestricted access to buyers across the globe.

hcls-flyer

Related articles

deloitte-centre-for-health-solutions

The Deloitte Centre for Health Solutions

Turning evidence into action
Read more
future-of-diagnostics

The Future of Diagnostics

Read more
Digital transformation

Seize the digital momentum

Measuring the return from pharmaceutical innovation 2022
Read more
Digital transformation

Intelligent post-launch patient support

Enhancing patient safety with AI
Read more